The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products ...